876-88-0

Basic information

• Product Name: 6-bromocinnolin-4-ol
• Synonyms: 6-bromocinnolin-4-ol;6-Bromo-4-cinnolinol
• CAS NO: 876-88-0
• Molecular Formula: C₈H₅BrN₂O
• Molecular Weight: 225.0421
• Mol File: 876-88-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 276-277 °C
• Boiling Point: 374.174°C at 760 mmHg
• Flash Point: 180.095°C
• Appearance: /
• Density: 1.822g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.721
• Storage Temp.: 2-8°C
• PKA: 2.32±0.40(Predicted)
• CAS DataBase Reference: 6-bromocinnolin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromocinnolin-4-ol(876-88-0)
• EPA Substance Registry System: 6-bromocinnolin-4-ol(876-88-0)

Safety Data

• Hazardous Substances Data: 876-88-0(Hazardous Substances Data)

Usage

General Description

6-bromocinnolin-4-ol is a chemical compound with the molecular formula C9H5BrN2O. It is a brominated derivative of cinnolin-4-ol, containing a bromine atom attached to the sixth carbon of the cinnoline ring. 6-bromocinnolin-4-ol has potential applications in the field of medicinal chemistry and drug development, as brominated cinnolinol derivatives have been studied for their anti-tumor and anti-inflammatory properties. Its structure and properties make it a potential candidate for further research and development in pharmaceutical and related industries. Additionally, its bromine substitution may confer specific chemical and biological activities that could be explored for various applications in the fields of medicine and materials science.

InChI:InChI=1/C8H5BrN2O/c9-5-1-2-7-6(3-5)8(12)4-10-11-7/h1-4H,(H,11,12)

Upstream product

• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 29124-64-9 N-(2-acetyl-4-bromophenyl)acetamide 
• 5234-26-4 N-(2-acetylphenyl)acetamide 
• 551-93-9 2-aminoacetophenone 
• 13631-76-0 (4-bromo-phenylhydrazono)-malonic acid diethyl ester 
• 624-19-1 4-bromoaniline hydrochloride 
• 20357-04-4 (5-bromo-2-nitro-phenyl)-propiolic acid 
• 90271-82-2 (4-bromo-phenylhydrazono)-malonyl chloride 
• 90484-39-2 (4-bromo-phenylhydrazono)-malonic acid 
• 61588-11-2 6-bromo-4-oxo-1,4-dihydro-3-cinnolinecarboxylic acid 

Downstream Products

• 68211-13-2 4,6-dichlorocinnoline 
• 68211-15-4 6-bromo-4-chlorocinnoline 
• 872284-86-1 6-bromo-3-chloro-1H-cinnolin-4-one 
• 1366050-69-2 2-(4-(6-bromo-3-nitrocinnolin-4-ylamino)phenyl)-2-methylpropanenitrile 
• 1366050-70-5 2-(4-(3-amino-6-bromocinnolin-4-ylamino)phenyl)-2-methylpropanenitrile 
• 1366050-29-4 2-(4-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1366050-71-6 2-(4-(8-bromo-1H-imidazo[4,5-c]cinnolin-1-yl)phenyl)-2-methylpropanenitrile 

Relevant articles and documents

Cnoline compound PI3K kinase inhibitor as well as preparation method and application thereof in pharmacy

The invention provides a cinnoline compound PI3K kinase inhibitor as shown in a formula I. In the cinnoline compound PI3K kinase inhibitor, and R1, R2 and R3 are defined in the specification. The invention also provides a pharmaceutical composition of the

Novel 4-(1H-1,2,3-triazol-4-yl)methoxy)cinnolines as potent antibacterial agents: Synthesis and molecular docking study

A new series of cinnoline-1,2,3-triazole derivatives were designed and synthesized by adopting Cu(1) catalyzed regeoselective1,3-dipolar cycloaddition reaction of terminal alkyne and azide. The in vitro antibacterial activity of all these compounds revealed that compounds 9d, 10a, 10b, and 10c are more potent antibacterial agents. Among the series, compound 4-(3-(4-((cinnolin-4-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)morpholine (10b) exhibited the most potent antibacterial activity against all tested gram-positive and gram-negative bacterial strains. Furthermore, molecular docking studies were also performed to understand the binding interactions of the most active analogs 9d, 10a, 10b, and 10c with Elastase of Pseudomonas aeruginosa (PDB: 1U4G). The results indicated that these classes of compounds have potential antibacterial activity, especially the compound 10b may serve as a promising antibacterial lead compound that could be further optimized for the further development of antibacterial drugs.

Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR

The identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cell assays, and good pharmacokinetic profile. Furthermore, compound 31 demonstrated in vivo efficacy in a PC-3M tumor xenograft model.